Printer Friendly

Development of an immunoassay for the kidney-specific protein myo-inositol oxygenase, a potential biomarker of acute kidney injury.

Acute kidney injury (AKI) (5) is common among hospitalized and critically ill patients, and its incidence is increasing (1-3). Approximately 45% of critically ill patients and 20% of hospitalized patients develop AKI (2, 4). This results in increased hospital stays, infectious complications, and increased mortality, at significant cost (5-8). Recent studies have linked AKI with future development of chronic kidney disease (9, 10). Multiple factors contribute to the development of AKI including sepsis, ischemia, drugs, intravenous contrast, and infection (11-16).

The current standard for identifying AKI, plasma creatinine, is nonspecific and insensitive (14, 17, 18). Plasma creatinine may not increase until days after injury or 50% of renal function is lost. Plasma creatinine is unable to accurately predict glomerular filtration rate (GFR) in the non-steady state of AKI, underestimating the renal function decline. Last, because creatinine depends on muscle mass and hepatic function, its plasma concentration may differ depending on these factors (14, 17, 18).

There is a critical unmet need for a real-time, specific, and sensitive AKI biomarker. The American Society of Nephrology, Acute Dialysis Quality Initiative, and Acute Kidney Injury Network (AKIN) have prioritized the identification and validation of AKI biomarkers (3, 19). Early detection of AKI may allow for timely intervention and perhaps decrease its significant morbidity and mortality (20). Although multiple new drugs have been developed to treat AKI, they have not proven effective in the clinical setting (21-27). This has been attributed, in part, to the inability to detect AKI early. Multiple studies have investigated a variety of blood and urine biomarkers for the diagnosis of AKI including interleukin (IL)-18, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1), among others (28-32). Although substantial progress has been made, no specific, early biomarkers of AKI have translated into clinical practice.

Renal tubular proteins are ideal biomarkers of AKI, as it is well established that tubular damage is an early event in renal ischemia. Although both proximal and distal tubules are injured, the S3 segment of the proximal tubule located in the outer medulla is particularly sensitive to decreased blood flow (7, 33). When tubular injury occurs, proximal tubular proteins may leak into the extratubular space and be excreted into urine or reabsorbed into blood.

In the current study, we identified myo-inositol oxygenase (MIOX) as a kidney-specific protein highly concentrated in the proximal tubule. We developed a sensitive immunoassay to measure plasma MIOX and investigated the utility of plasma MIOX as an AKI biomarker in an animal model of AKI and samples retrospectively obtained from critically ill human patients.



We identified kidney-specific genes according to methods described previously (34). Briefly, brain, liver, spleen, kidney, skeletal muscle, lung, pancreas, heart, and small intestine were dissected from 3 C57Bl/6 mice and snap frozen in liquid nitrogen. Total RNA was isolated, converted into biotinylated complementary RNA (cRNA), fragmented, and applied to mouse MU75A (version 1) GeneChip arrays (Affymetrix). The fluorescence intensity was scaled to 1500, and the mean difference values were calculated with Affymetrix software by measuring the difference between the perfect match and mismatch oligonucleotides. We mined these data for genes with mean difference values >10 000 in the kidney, expressed at > 10-fold amounts in the kidney relative to other tissues, and expressed in the proximal tubule.


The nucleotide sequence for human MIOX was inserted into a pGEX-4T1 vector (Life Technologies) for production in Escherichia coli. Recombinant MIOX was purified by use of immobilized glutathione (Pierce Chemical Co.) according to the manufacturer's instructions. We analyzed purified protein using Lonza precast 10%-20% SDS-PAGE with Novex prestained protein markers (Life Technologies) to confirm purity. We estimated concentrations using absorbance at 280 nm with calculated extinction coefficients. MIOX and glutathione S-transferase (GST) sequences were obtained from the Swiss-Prot website ( Recombinant GST-MIOX was cleaved with thrombin to obtain recombinant MIOX (rMIOX) devoid of GST. We analyzed this material by denaturing gel electrophoresis and N-terminal Edman sequencing to confirm purity and identity.


Rabbit polyclonal antibodies were produced at Harlan Bioproducts for Science with recombinant GST-MIOX as an immunogen. Polyclonal antibodies were purified by first removing cross-reacting anti-GST with a GST column (Pierce) according to the manufacturer's instructions. Antibodies were then affinity purified as described previously (35). Mouse monoclonal antibodies were produced at Maine Biotechnology Services with recombinant GST-MIOX as the immunogen. Monoclonal antibodies were purified by use of a protein A-agarose column, dialyzed against phosphate-buffered saline, pH 7.2, containing 0.05% Na[N.sub.3], and quantified by absorbance at 280 nm. We typed monoclonal antibodies using isotyping cassettes (Pierce). Epitope mapping was performed by use of Abimed spot peptide arrays as described previously (34). Briefly, peptide spot arrays composed of MIOX residues 1-10, 3-12, 5-14, and so on were probed with the anti-MIOX antibodies. We analyzed the epitope sequences by basic local alignment search text (BLAST) using a nonredundant Homo sapiens database and default algorithm parameters (http://blast.ncbi.nlm.


Normal human kidney homogenate and premade tissue blots were purchased from G-Biosciences. We performed Western blotting as previously described (34). Briefly, blots were probed with 4 [micro]g/mL polyclonal or monoclonal antibody. Where indicated, both monoclonal antibodies were used simultaneously at the above concentrations. Antispecies GAR-AP and GAM-AP (Jackson ImmunoResearch Laboratories) were used as detection antibodies at a 1:1000 dilution.


Formalin-fixed paraffin-embedded human kidney tissue was obtained from the Lauren V. Ackerman Laboratory of Surgical Pathology at Barnes Hospital. Samples were obtained from the uninvolved portions of kidneys resected for renal cell carcinoma. Single sections were stained after sodium citrate antigen retrieval by use of a Ventana autostainer as described previously (36). We used a final concentration of 5 [micro]g/mL of the rabbit polyclonal anti-MIOX antibody.


We developed a sandwich immunoassay for MIOX using monoclonal antibody 12H06 as capture antibody and biotinylated monoclonal antibody 01D10 as a capping antibody. We used this immunoassay to measure MIOX from human and mouse samples. Biotinylation of antibody 01D10 was performed by use of Sulfo NHS-LC-Biotin (Pierce) according to the manufacturer's instructions. The capture antibody was added to the plate at a concentration of 30 [micro]g/mL. The capping antibody was used at a concentration of 0.33 [micro]g/mL. Nonspecific binding was blocked by use of Pierce Superblock, mouse immunoglobulin G (Equitech-Bio), and 0.5 g/L Tween-20 (Sigma-Aldrich). Plasma samples, controls, and standards were diluted 1:8 in Superblock, mouse IgG, and Tween-20 before analysis. GSTM-IOX was serially diluted for construction of a standard curve. We determined the concentration of GST-MIOX using amino acid analysis (AAA Services Lab). Streptavidin conjugated to ruthenium (MesoScale Discovery) was added to samples and detected byuse ofa MesoScale Discovery Sector 2400 electrochemiluminescent plate reader. Spike recovery was determined by adding recombinant MIOX to a final concentration of either 2 or 10 ng/mL to control human heparin plasma. Dilutional linearity was evaluated by adding recombinant MIOX to a final concentration of 5 ng/mL to 1:8, 1:16,1:32, and 1:64 dilutions of control human heparin plasma.


All animal studies were approved by the Animal Studies Committee of Washington University School of Medicine. We used C57Bl/6 mice (3 female and 4 male) ranging in age from 8 to 12 weeks. One week before surgery, serum was collected and frozen at -80 [degrees]C. Animals were subjected to bilateral renal ischemia for 30 min. Briefly, animals were anesthetized with a mixture of ketamine and xylazine, their body temperature was maintained at 37[degrees]C on a heating pad and monitored with a rectal probe throughout surgery, and ischemia was induced by bilateral clamping of renal vascular pedicles for 30 min. Two sham-operated animals (1 male and 1 female) underwent an identical procedure without vascular pedicle clamping. Twenty-four hours after surgery, the animals were killed, serum was collected, and kidneys were perfused with 4% paraformaldehyde and placed in 4% paraformaldehyde (pH 7.4). Serum was stored at -80[degrees]C before immunoassay as described above for human plasma. We processed tissues for routine hematoxylin and eosin (H&E) staining according to standard procedures.


All human studies were approved by the internal review board for human studies at Washington University School of Medicine. Over a period of 2 years, laboratory data from adult patients in the surgical or medical intensive care units were screened for increases in plasma creatinine occurring over a 24- to 72-h time period. Laboratory data were also screened from age-matched patients in the surgical or medical intensive care units or on hospital floors for stable plasma creatinine over 72 h. Patients with chronic kidney disease or who did not have Foley catheters were not included. We obtained remnant heparin plasma samples from the Clinical Chemistry Laboratory of Barnes Hospital. We obtained plasma samples before the increase in plasma creatinine (designated time 0 h) and at the time of the plasma creatinine increase (designated time 54 h). For patients with stable plasma creatinine, 1 representative sample was retrieved from the Clinical Chemistry Laboratory. Aliquots (500 [micro]L) of plasma were prepared and frozen at -80[degrees]C before analysis. We reviewed patient medical records for demographic information, urine output, and diagnosis. Oliguria was defined as a urine output <0.5 mL/kg/h for at least 6 h.


Quantitative data are presented as mean (SE) unless otherwise indicated. All statistical analyses were performed by use of GraphPad Prism software. Comparison of multiple groups of patients and animals was evaluated by use of the Kruskal-Wallis test with Dunn correction for post hoc tests. Standard curves were generated by use of a 4-parameter logistic curve fit with 1/year weighting. Significance was defined as P < 0.05.



We sought to identify mouse genes expressed in the kidney by a factor of at least 10-fold compared with other tissues. Using this strategy, we identified myoinositol oxygenase (Miox) as a renal-specific, abundant gene (Fig. 1A). The Miox gene encodes the protein myo-inositol oxygenase (Miox). To confirm the tissue-specific nature of the human homolog of Miox, human tissue homogenates from liver, brain, lung, kidney, spleen, testis, ovary, heart, and pancreas were probed by use of an anti-MIOX rabbit polyclonal antibody. Consistent with the mouse gene profiling data, MIOX protein was detected only in human kidney homogenate (Fig. 1B).



Rabbit polyclonal and mouse monoclonal anti-MIOX antibodies were generated by use of recombinant GST-tagged MIOX as antigen. To confirm the identity of recombinant GST-MIOX, the protein was first cleaved into GST and MIOX with thrombin. The cleaved proteins were separated by use of SDS-PAGE and subjected to Edman sequencing (Fig. 2A). The protein migrating between 26 and 37 kDa gave a sequence of GSPEFKVTVG corresponding to the N terminus of MIOX. The protein near 26 kDa gave a sequence of MSPILGYWKI corresponding to the N terminus of S. japonicum GST. Both monoclonal antibodies were isotyped and found to be IgG2bK. Western blots were used to confirm the antibodies' ability to recognize recombinant MIOX and endogenous MIOX present in normal human kidney homogenate (Fig. 2A). The polyclonal and monoclonal antibodies recognized a protein with molecular mass between 26 and 37 kDa that comigrated with the recombinant MIOX protein (Fig. 2A). These results are consistent with the expected molecular weight of MIOX, 33 kDa.

The linear epitopes of the anti-MIOX antibodies were determined by use of spot-peptide membrane arrays containing the full-length amino acid sequence of MIOX. The 2 mouse monoclonal antibodies mapped to opposite ends of the MIOX sequence (Fig. 2B). The antibody designated 01D10 mapped to the N-terminal sequence of MIOX (Fig. 2C). The mouse monoclonal antibody designated 12H06 mapped to the C-terminal region of MIOX (Fig. 2C). Human MIOX showed 89.8% homology to mouse Miox. The peptide epitope recognized by the 12H06 mouse monoclonal antibody was 100% identical to the corresponding mouse Miox peptide sequence. The epitope recognized by the 01D10 mouse monoclonal antibody differed by 1 amino acid: the valine at amino acid position 21 is replaced by a methionine in mouse Miox. The rabbit anti-MIOX polyclonal antibody R9544 demonstrated 5 regions of intense staining, a finding consistent with the polyclonal nature of this antibody (Fig. 2C). Each monoclonal epitope sequence was validated for its uniqueness in a nonredundant Homo sapiens database by use of BLAST. A critical output parameter from BLAST is the expected value (E value). The E value is a measure of the chance that a random alignment from the probed database would produce the same normalized score. On the basis of the E value, there is a < 1 in 1 000 000 chance that the epitope sequences could be randomly found in the database (data not shown). The lowest E value of a non-MIOX protein was 2.3, compared to a MIOX E value of 1 X [10.sup.-6], indicating the highly specific nature of the antibody epitopes. Individual peptides corresponding to the mapped epitopes for both monoclonal antibodies were produced. Preincubation by use of the N-terminal peptide epitope, but not the C-terminal peptide epitope, inhibited binding of the 01D10 mouse monoclonal anti-MIOX antibody to a MIOX spot-peptide array. Similarly, preincubation by use of the C-terminal peptide epitope, but not the N-terminal peptide epitope, inhibited binding of the 12H06 mouse monoclonal anti-MIOX antibody to a MIOX spot-peptide array (data not shown).


Human kidney tissues were obtained from uninvolved portions of partial nephrectomy samples from patients with renal cell carcinoma. Single formalin-fixed paraffin-embedded tissue sections were stained with rabbit polyclonal anti-MIOX antibody. Consistent with previous studies, the MIOX protein showed strong cytoplasmic immunoreactivity in cells morphologically consistent with proximal tubules (Fig. 3) (37).



The mouse monoclonal antibodies were optimized for use in a sandwich immunoassay. The monoclonal antibody 12H06 was used as a capture antibody and biotinylated monoclonal antibody 01D10 was used as a capping antibody. The immunoassay performance characteristics are summarized in Supplemental Table 1, which accompanies the online version of this article at The limit of detection, defined as a signal-to-noise ratio of 2 relative to background, was 115 (55) pg/mL [n = 13, mean (SD)]. Human plasma samples stored at 4 [degrees]C or -80 [degrees]C for 10 days showed no significant difference in MIOX concentration [absolute mean % difference = 7.4% (4.0%), mean % difference = -0.4% (9.4%); n = 4]. The interassay CV was 15.2% (3.4%) [mean MIOX concentration 5.6 (0.7) ng/mL, n = 9]. All samples underwent 2 freeze-thaw cycles. The intraassay CV, determined by use of 19 plasma samples with a mean MIOX concentration of 21.2 ng/mL, range 1.7-48.2 ng/mL, was 7.9% (5.2%). GST-MIOX spiked into human heparinized plasma demonstrated 94% (19%) recovery of the expected signal (n = 8). The MIOX immunoassay demonstrated dilutional linearity recovery of 109% (12%) (n = 9) (see online Supplemental Fig. 1).


Miox was not detected in the serum of normal or sham-operated mice 24 h postoperatively (Fig. 4A). In contrast, Miox was markedly increased in the serum of mice 24 h after 30 min of bilateral ischemia reperfusion injury (Fig. 4A). Histologic examination of kidneys from sham-operated animals showed no evidence of tubular necrosis (Fig. 4B). In contrast, histologic examination revealed significant tubular necrosis in the kidneys of the experimental mice 24 h after injury (Fig. 4C).


Patients in an intensive care unit were screened for AKI, defined according to the AKIN criteria (3). Patients were screened for plasma creatinine increases of at least 1.5 times baseline or an absolute increase of 0.3 mg/dL (0.027 mmol/L) over 1-3 days. Once a patient was identified who had an increase in plasma creatinine, remnant heparin plasma samples were collected from the Barnes Hospital Clinical Chemistry Laboratory at the time of the plasma creatinine increase and 1-3 days before the plasma creatinine increase (time 0). Plasma creatinine increased a mean (SE) of 54 (3.8) h (n = 33; time 54) after the time 0 sample. Patient characteristics are summarized in Table 1. Oliguria was defined according to the AKIN criteria as <0.5 mL/kg/h for at least 6 h (3). A total of 42 patients fulfilled criteria for at least stage I AKI, defined as a relative increase in plasma creatinine of 50%, an absolute increase in plasma creatinine of 0.3 mg/dL (0.027 mmol/L), or a decrease in urine output to <0.5 mL/kg/h for at least 6h (3). Of the 42 patients with AKI, 33 had increases in plasma creatinine of at least 1.5 times baseline. Nine patients had a urine output of <0.5 mL/kg/h for at least 6 h without a change in plasma creatinine. Seventeen hospitalized or critically ill patients who did not meet criteria for AKI served as controls. There was no significant difference in age between the patient groups. There was a greater proportion of male patients within the AKI group. Plasma MIOX was measured in critically ill patients with AKI at time 0h(n = 42) and time 54 h (n = 37); the mean time plasma creatinine increased (Fig. 5). Samples were not available at the time of plasma creatinine increase for 5 patients. Plasma MIOX was significantly increased in patients with AKI at time 0 [12.4 (4.3) ng/mL] and at time 54 [10.1 (5.3) ng/mL] relative to controls [0.5 (0.3) ng/mL; P = 0.002]. Patients with oliguric AKI had significantly higher plasma MIOX values at time 0 [20.2 (7.5) ng/ mL, n = 23] and time 54 [17.1 (11.0) ng/mL, n = 17] compared with controls (P < 0.05) (Fig. 6). Significantly higher plasma MIOX concentrations were observed in patients with dialysis requiring AKI at time 0 [8.2 (3.5) ng/mL, n = 5] and time 54 [8.2 (3.1) ng/mL, n = 5] compared with controls (P < 0.05) (Fig. 6). All plasma MIOX concentrations were determined before initiation of dialysis. The increase in plasma MIOX preceded the increase in plasma creatinine by a mean of 54.3 (3.8) h (n = 33).





An ideal AKI biomarker should be kidney specific, rapidly detectable following injury, correlated with the degree of damage, and easily measured. A variety of approaches have been used to identify such a biomarker. In the current study, we first sought to identify kidney-specific genes. Because the proximal tubule is the major site of ischemic damage, genes specific to the proximal tubule were targeted. Using differential gene expression profiling, we identified MIOX as a renal-specific proximal tubule gene. Tissue specificity of MIOX was confirmed by use of Western blot. MIOX localized to the renal proximal tubule by use of immunohistochemistry. Mouse monoclonal anti-MIOX antibodies were developed and characterized. These monoclonal antibodies were optimized for use in a sandwich immunoassay to quantify MIOX in plasma. This assay was used to investigate MIOX as a biomarker of AKI. Mice subjected to bilateral renal ischemia-reperfusion showed increased plasma MIOX at 24-h postinjury. Critically ill patients with AKI showed increased plasma MIOX compared with control patients without AKI. Serum MIOX was highest in patients with oliguric and dialysis-requiring AKI. The increase in plasma MIOX occurred approximately 2 days before the increase in plasma creatinine.


MIOX is a renal-specific enzyme that catalyzes the first committed step in myo-inositol metabolism (38). The MIOX mRNA transcript is reportedly downregulated in a rat model of ischemic AKI (37). In this study, the authors hypothesized that MIOX mRNA loss was directly related to the degree of necrosis following renal ischemia. In the current study, demonstration of increased plasma MIOX following AKI may also be related to necrosis of the proximal tubule, although secretion cannot be ruled out.

It is noteworthy that MIOX was not detected in plasma of all patients with AKI defined by use of the AKIN criteria (3). Because the timing of renal injury was unknown in this patient population, it is possible that an increase in plasma MIOX may have occurred before or after samples were obtained. Plasma creatinine is a nonspecific biomarker of renal injury, so it is possible that a subset of patients developed increased plasma creatinine in the absence of proximal tubule cell damage.

Other proteins have been investigated as potential kidney injury biomarkers. Previous studies demonstrated that NGAL, KIM-1, a-GST, liver type fatty acid-binding protein 1 (FABP1), and N-acetyl-[beta]--D-glucosaminidase are detectable in urine following renal injury (32, 39, 40). However, none of these has yet translated into clinical use. In contrast to these biomarkers, MIOX is a kidney-specific protein. MIOX is also an endogenous kidney protein. Therefore, it may be released more rapidly than the inducible biomarkers KIM-1, NGAL, and FABP1. Measuring these analytes together may provide more detailed information regarding the timing of renal injury. Interestingly, MIOX did not appear to signal nonoliguric kidney injury in this retrospective study. It will be important to confirm this result in a prospective study. Nonetheless, it is most likely that a panel of biomarkers will be necessary to accurately detect AKI, determine severity, and localize the portion of the nephron injured in a given clinical scenario.

There are several limitations to this study. The human samples were collected in a retrospective manner from critically ill and hospitalized patients. The study population was screened for patients with clinical evidence of AKI and is therefore not an accurate representation of all critically ill patients. Because these samples were obtained retrospectively, they were not immediately frozen after collection. Rather, the samples were stored at 4[degrees]C for 1-7 days before aliquoting and freezing. Although the MIOX immunoassay does not appear to be significantly affected by storing plasma for up to 10 days at 4[degrees]C, it is important to note that the samples were not all handled identically. This may have introduced artifact into the analysis. Previous studies confirmed the kidney-specific nature of MIOX. However, it is unknown whether MIOX mRNA concentration patterns may change in other tissues following AKI or multiorgan failure. Additional studies are necessary to investigate the tissue profile of MIOX in these settings to explore the renal-specific nature of its origin.

In conclusion, we developed an immunoassay to quantify the kidney-specific protein MIOX in human plasma. We demonstrated that MIOX was increased in the serum of animals and the plasma of critically ill patients with AKI. In critically ill patients, MIOX increased approximately 2 days before the increase in plasma creatinine, potentially opening a therapeutic window. Additional studies are warranted to further investigate the potential of MIOX as an early, kidney-specific biomarker of AKI.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: None declared.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: NIH/NIDDK P20 DK097798 and NIH/NIDDK P30 DK 079333. J.P. Gaut, Washington University O'Brien Center for Kidney Disease Research Pilot and Feasibility Grant (P30 DK07933-05); S. Jain, NIH/NIDDK R01DK082531.

Expert Testimony: None declared.

Patents: D.L. Crimmins, C.M. Lockwood, J.H. Ladenson, and J.P. Gaut are named as coinventors on a pending patent filed by Washington University on kidney injury biomarkers.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.

Previously published online at DOI: 10.1373/clinchem.2013.212993

Received July 22, 2013; accepted January 15, 2014.

Acknowledgments: We thank Amanda Knoten for technical assistance with animal studies.


(1.) Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN--time for reappraisal. Crit Care 2009; 13:211.

(2.) Li PK, Burdmann EA, Mehta RL. Acute kidney injury: global health alert. Kidney Int 2013;83: 372-6.

(3.) Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.

(4.) Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 2012;380:756-66.

(5.) Himmelfarb J, Ikizler TA. Acute kidney injury: changing lexicography, definitions, and epidemiology. Kidney Int 2007;71:971-6.

(6.) Palevsky PM. Renal support in acute kidney injury: how much is enough? N Engl J Med 2009; 361:1699-701.

(7.) Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004;114:5-14.

(8.) Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012;81:819-25.

(9.) Bydash JR, Ishani A. Acute kidney injury and chronic kidney disease: a work in progress. Clin J Am Soc Nephrol 2011;6:2555-7.

(10.) Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012; 81:442-8.

(11.) Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. US renal data system 2010 annual data report. Am J Kidney Dis 2011; 57(1 Suppl 1):A8, e1-526.

(12.) Perazella MA. Drug use and nephrotoxicity in the intensive care unit. Kidney Int 2012;81:1172-8.

(13.) Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation 2010;122: 2451-5.

(14.) Star RA. Treatment of acute renal failure. Kidney Int 1998;54:1817-31.

(15.) Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-60.

(16.) Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol 2011;22:999-1006.

(17.) Bolignano D. Serum creatinine and the search for new biomarkers of acute kidney injury (AKI): the story continues. Clin Chem Lab Med 2012;50: 1495-9.

(18.) Waikar SS, Betensky RA, Bonventre JV. Creatinine as the gold standard for kidney injury biomarker studies? Nephrol Dial Transplant 2009;24: 3263-5.

(19.) Kellum JA, Mehta RL, Levin A, Molitoris BA, Warnock DG, Shah SV, et al. Development of a clinical research agenda for acute kidney injury using an international, interdisciplinary, three-step modified Delphi process. Clin J Am Soc Nephrol 2008;3:887-94.

(20.) Schrier RW. Need to intervene in established acute renal failure. J Am Soc Nephrol 2004;15: 2756-8.

(21.) Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997; 336:828-34.

(22.) Conger JD, Falk SA, Yuan BH, Schrier RW. Atrial natriuretic peptide and dopamine in a rat model of ischemic acute renal failure. Kidney Int 1989; 35:1126-32.

(23.) Denton MD, Chertow GM, Brady HR. "Renaldose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.

(24.) Hirschberg R, Kopple J, Lipsett P, Benjamin E, Minei J, Albertson T, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999;55:2423-32.

(25.) Noguchi S, Kashihara Y, Ikegami Y, Morimoto K, Miyamoto M, Nakao K. Insulin-like growth factor-I ameliorates transient ischemia-induced acute renal failure in rats. J Pharmacol Exp Ther 1993;267:919-26.

(26.) Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis 2005;46:26-34.

(27.) Acker CG, Singh AR, Flick RP, Bernardini J, Greenberg A, Johnson JP. A trial of thyroxine in acute renal failure. Kidney Int 2000;57:293-8.

(28.) Devarajan P. Review: Neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology (Carlton) 2010;15:419-28.

(29.) Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, et al. Renal biomarker qualification submission: a dialog between the FDAEMEA and Predictive Safety Testing Consortium. Nat Biotechnol 2010;28:455-62.

(30.) Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013;17:R25.

(31.) Waikar SS, Bonventre JV. Biomarkers for the diagnosis of acute kidney injury. Nephron Clin Pract 2008;109:c192-7.

(32.) Siew ED, Ware LB, Ikizler TA. Biological markers of acute kidney injury. J Am Soc Nephrol 2011; 22:810-20.

(33.) Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121:4210-21.

(34.) Laterza OF, Modur VR, Crimmins DL, Olander JV, Landt Y, Lee JM, Ladenson JH. Identification of novel brain biomarkers. Clin Chem 2006;52: 1713-21.

(35.) Crimmins DL, Brada NA, Lockwood CM, Griest TA, Waldemer RJ, Cervinski MA, et al. ETRAP (efficient trapping and purification) of target protein polyclonal antibodies from GST-protein immune sera. Biotechnol Appl Biochem 2010;57: 127-38.

(36.) Gaut JP, Crimmins DL, Lockwood CM, McQuillan JJ, Ladenson JH. Expression of the Na(+)/K(+)transporting ATPase gamma subunit FXYD2 in renal tumors. Mod Pathol 2013;26:716-24.

(37.) Hu E, Chen Z, Fredrickson T, Gellai M, Jugus M, Contino L, et al. Identification of a novel kidney-specific gene downregulated in acute ischemic renal failure. Am J Physiol Renal Physiol 2000; 279:F426-39.

(38.) Thorsell AG, Persson C, Voevodskaya N, Busam RD, Hammarstrom M, Graslund S, et al. Structural and biophysical characterization of human myoinositol oxygenase. J Biol Chem 2008;283: 15209-16.

(39.) Noiri E, Doi K, Negishi K, Tanaka T, Hamasaki Y, Fujita T, et al. Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol 2009;296:F669-79.

(40.) Westhuyzen J, Endre ZH, Reece G, Reith DM, Saltissi D, Morgan TJ. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 2003;18:543-51.

Joseph P. Gaut, [1] * Dan L. Crimmins, [2] Matt F. Ohlendorf, [2] Christina M. Lockwood, [2] Terry A. Griest, [2] Nancy A. Brada, [2] Masato Hoshi, [3] Bryan Sato, [4] Richard S. Hotchkiss, [4] Sanjay Jain, [1,3] and Jack H. Ladenson [2]

[1] Department of Pathology and Immunology, Division of Anatomic and Molecular Pathology, [2] Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, [3] Department of Medicine, Renal Division, [4] Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO.

* Address correspondence to this author at: Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8118, St. Louis, MO 63110. Fax 314-362-0107; e-mail

[5] Nonstandard abbreviations: AKI, acute kidney injury; GFR, glomerular filtration rate; AKIN, Acute Kidney Injury Network; IL, interleukin; NGAL, neutrophil gelatinase-associated lipocalin; KIM-1, kidney injury molecule 1; MIOX and Miox, myo-inositol oxygenase; cRNA, complementary RNA; GST, glutathione S-transferase; rMIOX, recombinant MIOX; BLAST, basic local alignment search text; H&E, hematoxylin and eosin; FABP1, liver type fatty acid-binding protein 1.
Table 1. Patient characteristics. (a)

                       No AKI (b)              AKI

n                          17                  42
Age, years               58 (4)              58 (2)
M:F                        8:9                24:18
Race, n (%)
  White                 14/17(82)          31/42 (74)
  African American      2/17(12)           10/42 (24)
  Hispanic                  0               1/42 (2)
  Unknown               1/17(6%)                0
Peak creatinine,      0.88 (0.08)      2.03 (0.17) [0.179
   mg/dL [mmol/L]    [0.078 (0.007)]      (0.015)] (b)
Peak blood urea        16(2) [5.7         36 (3) [12.9
   nitrogen, mg/dL       (0.7)]            (1.1)] (b)

                       Nonoliguric AKI        Oliguric AKI

n                            14                    23
Age, years                 63 (4)                56 (2)
M:F                          7:7                  14:9
Race, n (%)
  White                   11/14(79)            16/23 (70)
  African American        2/14(14)              7/23 (30)
  Hispanic                 1/14(7)                  0
  Unknown                     0                     0
Peak creatinine,     1.95 (0.12) [0.172    1.81 (0.19) [0.160
   mg/dL [mmol/L]         (0.011)]b           (0.017)] (b)
Peak blood urea         38 (4) [13.6          31 (2) [11.1
   nitrogen, mg/dL       (1.4)] (b)            (0.7)] (b)


n                             5
Age, years                 57 (8)
M:F                          3:2
Race, n (%)
  White                   4/5 (80)
  African American        1/5 (20)
  Hispanic                    0
  Unknown                     0
Peak creatinine,     3.28 (0.78) [0.290
   mg/dL [mmol/L]       (0.069)] (b)
Peak blood urea        57 (20) [20.3
   nitrogen, mg/dL       (7.1)] (b)

(a) Values are reported as mean (SE).

(b) Patients either hospitalized or critically ill who had no
significant increases in plasma creatinine or decreases in urine

(c) P < 0.005 compared with the control group (Kruskal-Wallis with
Dunn correction for post hoc tests).
COPYRIGHT 2014 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Proteomics and Protein Markers
Author:Gaut, Joseph P.; Crimmins, Dan L.; Ohlendorf, Matt F.; Lockwood, Christina M.; Griest, Terry A.; Bra
Publication:Clinical Chemistry
Article Type:Report
Date:May 1, 2014
Previous Article:Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study.
Next Article:Reference interval evaluation of high-sensitivity troponin T and N-terminal B-type natriuretic peptide in Vietnam and the US: the North South East...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters